by Will Sansom
Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect—high potassium levels in the blood (hyperkalemia).
Elevated potassium puts patients at risk of death from cardiac arrhythmias. Lacking a drug to treat the problem, doctors either stop these beneficial drugs or may use kidney dialysis to quickly lower the potassium.
At the National Kidney Foundation Spring Clinical Meetings March 25-29 in Dallas, UT Medicine San Antonio renal specialist Wajeh Y. Qunibi, M.D., presented results from two national studies of ZS-9, a new oral drug that has been tested in more than 1,000 patients with high blood potassium.
The results are in a subgroup of patients with chronic kidney disease treated with RAASI's.
Dr. Qunibi is professor of medicine in the School of Medicine at The University of Texas Health Science Center at San Antonio.
The studies evaluated the effectiveness and safety of ZS-9.
"Dialysis is logistically difficult for patients, requires a catheter and is expensive," Dr. Qunibi said. "In our studies, patients took a dose by mouth three times daily with meals, and potassium normalized in 98 percent of them within 48 hours.
"This is a major change in the way to treat hyperkalemia."
He said between 5 percent and 30 percent of patients, depending on the type and stage of chronic kidney disease and whether they are treated with one or more RAASI's, may develop this high potassium condition.
It is estimated that more than 20 million people in the U.S. have chronic kidney disease in varying levels of severity. Risk increases with age, and the disease is most common in adults over 70, particularly those with diabetes.
Results of the ZS-9 studies were reported in recent months in the New England Journal of Medicine and the Journal of the American Medical Association.
Explore further: Investigational drug reduces high potassium levels in chronic kidney disease patients
Medical Xpress on facebook
Related Stories
Investigational drug reduces high potassium levels in chronic kidney disease patients
Research published today found that the investigational drug patiromer decreased high potassium levels and maintained normal potassium levels in patients with chronic kidney disease. The results of a multicenter trial appear ...
Kidney patients living longer on dialysis, study shows
(HealthDay)—New statistics suggest that kidney patients on dialysis are surviving longer.
Study uncovers predictors of chronic kidney disease worsening in children and adolescents
Study results published today in the National Kidney Foundation's American Journal of Kidney Diseases provide new insights into why a child's chronic kidney disease (CKD) may worsen to kidney failure. Among ...
Dialysis patients may have faulty 'good' cholesterol
Kidney disease patients on dialysis often have impaired high-density lipoprotein (HDL) or "good" cholesterol, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN) ...
Drug lowers high potassium levels associated with potentially lethal cardiac arrhythmias
Mikhail Kosiborod, M.D., of Saint Luke's Mid America Heart Institute, Kansas City, and colleagues evaluated the efficacy and safety of the drug zirconium cyclosilicate in patients with hyperkalemia (higher than normal potassium ...
Recommended for you
Blood-based biomarkers could enable simple, accurate TB tests for diagnosis and monitoring
Researchers have identified blood-based biomarkers in patients with active tuberculosis (ATB) that could lead to new blood-based diagnostics and tools for monitoring treatment response and cure.
Guinea shuts border with Sierra Leone in effort to end Ebola
Guinea has closed its border with Sierra Leone as part of new efforts to stamp out Ebola.
Oxygen therapy in COPD patients is associated with burn injury
Researchers from the University of Texas Medical Branch at Galveston have found that patients with chronic obstructive pulmonary disease receiving home oxygen have a higher risk of burn injury. This study was published on ...
US Ebola patient's health improves again
An American healthcare worker who contracted the dangerous Ebola virus while working in Sierra Leone has improved and is now listed in fair condition, hospital officials said Monday.
Endoscopes linked to outbreak of drug-resistant E. coli
An outbreak of a novel Escherichia coli (E. coli) strain resistant to antibiotics has been linked to contaminated endoscopes in a Washington state hospital. The study indicates that industry standard clea ...
Fighting back against superbugs
Antibiotics—and antibiotic resistance—are in the news once again, with announcements by McDonald's and Costco that they will eliminate antibiotics that are important to human medicine from use in the ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
by Will Sansom
Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect—high potassium levels in the blood (hyperkalemia).
Elevated potassium puts patients at risk of death from cardiac arrhythmias. Lacking a drug to treat the problem, doctors either stop these beneficial drugs or may use kidney dialysis to quickly lower the potassium.
At the National Kidney Foundation Spring Clinical Meetings March 25-29 in Dallas, UT Medicine San Antonio renal specialist Wajeh Y. Qunibi, M.D., presented results from two national studies of ZS-9, a new oral drug that has been tested in more than 1,000 patients with high blood potassium.
The results are in a subgroup of patients with chronic kidney disease treated with RAASI's.
Dr. Qunibi is professor of medicine in the School of Medicine at The University of Texas Health Science Center at San Antonio.
The studies evaluated the effectiveness and safety of ZS-9.
"Dialysis is logistically difficult for patients, requires a catheter and is expensive," Dr. Qunibi said. "In our studies, patients took a dose by mouth three times daily with meals, and potassium normalized in 98 percent of them within 48 hours.
"This is a major change in the way to treat hyperkalemia."
He said between 5 percent and 30 percent of patients, depending on the type and stage of chronic kidney disease and whether they are treated with one or more RAASI's, may develop this high potassium condition.
It is estimated that more than 20 million people in the U.S. have chronic kidney disease in varying levels of severity. Risk increases with age, and the disease is most common in adults over 70, particularly those with diabetes.
Results of the ZS-9 studies were reported in recent months in the New England Journal of Medicine and the Journal of the American Medical Association.
Explore further: Investigational drug reduces high potassium levels in chronic kidney disease patients
Medical Xpress on facebook
Related Stories
Investigational drug reduces high potassium levels in chronic kidney disease patients
Research published today found that the investigational drug patiromer decreased high potassium levels and maintained normal potassium levels in patients with chronic kidney disease. The results of a multicenter trial appear ...
Kidney patients living longer on dialysis, study shows
(HealthDay)—New statistics suggest that kidney patients on dialysis are surviving longer.
Study uncovers predictors of chronic kidney disease worsening in children and adolescents
Study results published today in the National Kidney Foundation's American Journal of Kidney Diseases provide new insights into why a child's chronic kidney disease (CKD) may worsen to kidney failure. Among ...
Dialysis patients may have faulty 'good' cholesterol
Kidney disease patients on dialysis often have impaired high-density lipoprotein (HDL) or "good" cholesterol, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN) ...
Drug lowers high potassium levels associated with potentially lethal cardiac arrhythmias
Mikhail Kosiborod, M.D., of Saint Luke's Mid America Heart Institute, Kansas City, and colleagues evaluated the efficacy and safety of the drug zirconium cyclosilicate in patients with hyperkalemia (higher than normal potassium ...
Recommended for you
Blood-based biomarkers could enable simple, accurate TB tests for diagnosis and monitoring
Researchers have identified blood-based biomarkers in patients with active tuberculosis (ATB) that could lead to new blood-based diagnostics and tools for monitoring treatment response and cure.
Guinea shuts border with Sierra Leone in effort to end Ebola
Guinea has closed its border with Sierra Leone as part of new efforts to stamp out Ebola.
Oxygen therapy in COPD patients is associated with burn injury
Researchers from the University of Texas Medical Branch at Galveston have found that patients with chronic obstructive pulmonary disease receiving home oxygen have a higher risk of burn injury. This study was published on ...
US Ebola patient's health improves again
An American healthcare worker who contracted the dangerous Ebola virus while working in Sierra Leone has improved and is now listed in fair condition, hospital officials said Monday.
Endoscopes linked to outbreak of drug-resistant E. coli
An outbreak of a novel Escherichia coli (E. coli) strain resistant to antibiotics has been linked to contaminated endoscopes in a Washington state hospital. The study indicates that industry standard clea ...
Fighting back against superbugs
Antibiotics—and antibiotic resistance—are in the news once again, with announcements by McDonald's and Costco that they will eliminate antibiotics that are important to human medicine from use in the ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment